Psychomotor Effects of Alprazolam and Diazepam during Acute and Subacute Treatment, and during the Follow‐up Phase
The DOI matches its Crossref record.
Abstract
Psychomotor effects of alprazolam (AZ) and diazepam (DZ) were compared in a controlled double‐blind and cross‐over trial in 24 student volunteers, who received, three times daily, placebo for the first 4 days, then an active drug (AZ) 0.25 mg or DZ 5 mg) for 7 days, and again placebo for 3 days. After a 3 week wash‐out period the procedure was repeated with the comparative drug. Objective and subjective measurements were made on day 3 (placebo), on days 4 and 10 (active drug) and on days 11, 12 and 13 (follow‐up placebo). Baseline levels were measured in the morning, a capsule was taken, and the tests were repeated 2 hours and 8 hours later. Blood samples were taken in the afternoon of day 10 for the bioassay of serum benzodiazepine concentrations. Single doses of both AZ 0.25 mg and DZ 5 mg showed similar degree of impairment in several objective tests. At the end of the 7‐day maintenance DZ (15 mg daily) proved significantly more sedative and impaired more psychomotor performance than AZ (0.75 mg daily) did. Improvement of the complex test performances (a learning effect) was counteracted by DZ more than by AZ. No actual development of tolerance was demonstrated after either drug. During the follow‐up placebo phase, DZ showed more objective residual effects than AZ. The Maddox wing test (exophoria) showed a significant DZ effect to be still present on the third post‐treatment day. However, during the follow‐up period subjects reported subjectively more sedation and clumsiness after AZ than after DZ, but this was not associated with impairment of objective skills.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
Cognitive impairment in long-term benzodiazepine users
Golombok, S., Moodley, P., & Lader, M. (1988) · Psychological Medicine · doi:10.1017/s0033291700007911 · Cited by 167
“1983; Golombok & Lader, 1984), to counteract the improvement in performance expected by practice effects (Aranko et al. 1985), and to become significantly worse (Lader et al.”
BackgroundAllen, D., Curran, H. V., & Lader, M. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00265843 · Cited by 51
“Kales et al. (1987) and Aranko et al. (1985) have both reported "rebound phenomena" following withdrawal of alprazolam.”
BackgroundThe natural history of tolerance to the benzodiazepines
Higgitt, A., Fonagy, P., & Lader, M. (1988) · Psychological Medicine. Monograph Supplement · doi:10.1017/s0264180100000412 · Cited by 37
Metadata
- Authors
- Aranko, K., Mattila, M. J., & Bordignon, D.
- Venue
- Acta Pharmacologica et Toxicologica
- Publisher
- Wiley
- Published
- 1985-05
- Volume
- 56
- Issue
- 5
- Pages
- 364-372
- ISSN
- 0001-6683 (ISSN-L)
- OpenAlex
- W2004831100
- Cited by
- 27
- References
- 0
- FWCI
- 18.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychomotor Effects of Alprazolam and Diazepam during Acute and Subacute Treatment, and during the Follow‐up Phase. https://app.cochat.ai/papers/10.1111/j.1600-0773.1985.tb01305.x
- The paper
- Aranko, K., Mattila, M. J., & Bordignon, D. (1985). Psychomotor Effects of Alprazolam and Diazepam during Acute and Subacute Treatment, and during the Follow‐up Phase. Acta Pharmacologica et Toxicologica. https://doi.org/10.1111/j.1600-0773.1985.tb01305.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.